-
Innovation Ranking
Innovation Ranking – S&P Global Inc
S&P Global Inc (SPGI) is a provider of financial intelligence solutions. It offers credit ratings, benchmarks, data, and digital and traditional financial research and analytical tools to the capital and commodity markets globally. The company provides cross-asset analytics, multi-asset-class data, benchmark prices, desktop services, and investment information. SPGI is a provider of information and benchmark prices for the commodity and energy markets. It also maintains various valuation and index benchmarks for wealth managers, investment advisors, and institutional investors. The company...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Kidney Cancer (Renal Cell Cancer) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-CD19CD20-ALLO1 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-CD19CD20-ALLO1 in Diffuse Large B-Cell Lymphoma Drug Details: P-CD19CD20-ALL01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-CD19CD20-ALLO1 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-CD19CD20-ALLO1 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-CD19CD20-ALLO1 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-CD19CD20-ALLO1 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-CD19CD20-ALLO1 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-CD19CD20-ALLO1 in Primary Mediastinal B-Cell Lymphoma Drug Details: P-CD19CD20-ALL01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-CD19CD20-ALLO1 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-CD19CD20-ALLO1 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-CD19CD20-ALLO1 in Marginal Zone B-cell Lymphoma Drug Details: P-CD19CD20-ALL01...
-
Innovation Ranking
Innovation Ranking – Zhong An Online P&C Insurance Co., Ltd
Zhong An Online P&C Insurance Co Ltd (Zhong An) is a provider of online insurance services. The company's offerings include health insurance, bond insurance, accident insurance, motor insurance, credit insurance, cargo insurance, liability insurance, household property insurance and shipping return insurance. Through its subsidiary, the company provides technology solutions and data analytics and information in the domestic and overseas insurance industry. Zhong An is headquartered in Shanghai, China.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer Drug Details: P-MUC1CALLO-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC) Drug Details: P-MUC1CALLO-1...